Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009972 | 0.80 | GRIN1 (0.49) | EPHX2DPP4 | |
| SCHEMBL5501491 | 0.71 | DPP4 (0.40) | EPHX2DPP4DPP7EPHX1 | |
| SCHEMBL6008654 | 0.71 | LMNA (0.37) | EPHX2SMN1; SMN2 | |
| SCHEMBL3188537 | 0.70 | GRIN2D (0.50) | EPHX2DPP4DPP7EPHX1 | |
| SCHEMBL9298243 | 0.69 | FDPS (0.41) | EPHX2DPP4EPHX1 | |
| SCHEMBL1150778 | 0.67 | EPHX2 (0.55) | EPHX2DPP4DPP7EPHX1 | |
| SCHEMBL2697743 | 0.67 | EPHX2 (0.55) | EPHX2DPP4DPP7EPHX1 | |
| SCHEMBL1082075 | 0.66 | EPHX2 (0.50) | EPHX2DPP4DPP7EPHX1 | |
| SCHEMBL9298883 | 0.65 | HTT (0.58) | EPHX2DPP4EPHX1 | |
| SCHEMBL5505001 | 0.65 | HTT (0.36) | EPHX2DPP4DPP7EPHX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | EPHX2 312/4885DPP4 1442/4885DPP7 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.